Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Multiple myeloma. New approaches to therapy.

Dunbar CE, Nienhuis AW.

JAMA. 1993 May 12;269(18):2412-6. No abstract available.

PMID:
7683062
2.

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.

Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B.

Blood. 1992 Oct 1;80(7):1666-72.

3.

Intensive combined therapy for previously untreated aggressive myeloma.

Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, Mazieres B, Pris J, Laurent G.

Blood. 1992 Mar 1;79(5):1130-6.

5.

Newer approaches to the therapy of multiple myeloma.

Kyle RA.

Blood. 1990 Nov 1;76(9):1678-9. No abstract available.

6.

Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma.

Vivancos P, Sarrá J, Palou J, Valls A, Garćia J, Grañena A.

Bone Marrow Transplant. 1996 Apr;17(4):669-71.

PMID:
8722373
7.

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M.

Leukemia. 2000 Jul;14(7):1310-3.

PMID:
10914557
8.

High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma.

Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, Haas R.

Ann Oncol. 1997 Mar;8(3):243-6.

PMID:
9137792
9.

Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study.

Feremans W, Le Moine F, Ravoet C, Lambermont M, Bastin G, Delville JP, Pradier O, Dupont E, Capel P.

Am J Hematol. 1994 Oct;47(2):135-8.

PMID:
7522395
10.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

12.

[Treatments of multiple myeloma in 1992].

Monconduit M.

Rev Med Interne. 1992 Jul-Aug;13(4):315-8. Review. French.

PMID:
1363152
13.

Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.

Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, et al.

Blood. 1995 Jun 1;85(11):3048-57.

14.

Transplantation in multiple myeloma.

Topolsky D, Biggs D.

Semin Oncol. 1995 Jun;22(3):230-7. Review. No abstract available.

PMID:
7777867
15.

Factors influencing platelet recovery after blood cell transplantation in multiple myeloma.

Gertz MA, Lacy MQ, Inwards DJ, Pineda AA, Chen MG, Gastineau DA, Tefferi A, Kyle RA, Litzow MR.

Bone Marrow Transplant. 1997 Sep;20(5):375-80.

16.
17.

Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma.

Devine SM, Jahagirdar B, van Besien K.

Blood. 2002 Jun 1;99(11):4251-2; author reply 4252. No abstract available.

18.

Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer.

Dunbar CE, Nienhuis AW, Stewart FM, Quesenberry P, O'Shaughnessy J, Cowan K, Cottler-Fox M, Leitman S, Goodman S, Sorrentino BP, et al.

Hum Gene Ther. 1993 Apr;4(2):205-22. No abstract available.

PMID:
8098622
19.

T-cell depleted bone marrow transplantation for plasma cell myeloma. Report of a case and review of the results of BMT for myeloma.

Yehuda AB, Or R, Naparstek E, Slavin S, Polliack A.

Blut. 1988 May;56(5):229-31. Review.

PMID:
3285913
20.

Standard therapy versus autologous transplantation in multiple myeloma.

Attal M, Harousseau JL.

Hematol Oncol Clin North Am. 1997 Feb;11(1):133-46.

PMID:
9081208

Supplemental Content

Support Center